Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase (ALK)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Large-scale testing (Phase 3)Active Not RecruitingNCT02767804
What this trial is testing

EXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Xcovery Holdings, Inc. 290
Not applicableUnknownNCT03236675
What this trial is testing

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Exosome Diagnostics, Inc. 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Large-scale testing (Phase 3)Study completedNCT00932893
What this trial is testing

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 347
Testing effectiveness (Phase 2)Study completedNCT03155009
What this trial is testing

The Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 44
Not applicableLooking for participantsNCT05724004
What this trial is testing

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

Who this might be right for
Radiotherapy Side EffectNon-small Cell Lung CancerALK Gene Mutation
Karolinska University Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Post-approval studies (Phase 4)Study completedNCT04362072
What this trial is testing

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
CarcinomaNon-Small-Cell Lung
Pfizer 71
Large-scale testing (Phase 3)Study completedNCT03596866
What this trial is testing

Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Who this might be right for
ALK+ Advanced NSCLC
Takeda 248
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Early research (Phase 1)Looking for participantsNCT07617337
What this trial is testing

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Chugai Pharmaceutical 102
Not applicableLooking for participantsNCT03042221
What this trial is testing

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Who this might be right for
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more
University of Colorado, Denver 100
Not applicableLooking for participantsNCT06361589
What this trial is testing

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Who this might be right for
ALK-positive Non-small Cell Lung CancerReal World Study
Sichuan Cancer Hospital and Research Institute 200
Testing effectiveness (Phase 2)Looking for participantsNCT06362369
What this trial is testing

Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Who this might be right for
Advanced CancerAdvanced Solid TumorMelanoma+15 more
7 Hills Pharma, LLC 126
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Testing effectiveness (Phase 2)Ended earlyNCT02521051
What this trial is testing

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 11
Post-approval studies (Phase 4)Active Not RecruitingNCT05160922
What this trial is testing

Crizotinib Continuation Clinical Study

Who this might be right for
NSCLCALCLIMT
Pfizer 27
Large-scale testing (Phase 3)UnknownNCT05204628
What this trial is testing

Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 238
Testing effectiveness (Phase 2)Study completedNCT00932451
What this trial is testing

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 1,069
Next Page